| 张楠 屈凯 于小勇 李现成 罗艳.百令胶囊联合厄贝沙坦片对膜性肾病患者MMP-9, MMP-3和TIMP-1水平的影响[J].,2016,16(28):5475-5478 |
| 百令胶囊联合厄贝沙坦片对膜性肾病患者MMP-9, MMP-3和TIMP-1水平的影响 |
| Effect of Corbrin and Irbesartan on SerumLevels of MMP- 9, MMP-3 andTIMP-1 of Patients with Membranous Nephropathy |
| |
| DOI： |
| 中文关键词: 膜性肾病 基质金属蛋白酶-9 基质金属蛋白酶-3 金属蛋白酶组织抑制物-1 |
| 英文关键词: Membranous nephropathy MMP-9 MMP-3 TIMP-1 |
| 基金项目:陕西省自然科学基金项目(2007C231) |
|
| 摘要点击次数: 891 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探究百令胶囊联合厄贝沙坦片对膜性肾病患者基质金属蛋白酶-9、3 和金属蛋白酶组织抑制物-1 影响。方法：收集我
院肾内科收治的膜性肾病患者98例，根据随机对照表分为对照组和试验组，每组49 例。对照组给予厄贝沙坦片治疗，试验组联
合百令胶囊治疗。对比分析两组患者的临床疗效、血清Scr、BUN、UA、Ccr、尿蛋白、MMP-9、MMP-3 及TIMP-l 水平以及不良反应
的发生情况。结果：治疗后，对照组临床总有效率为81.63%，显著低于试验组的95.92%(P＜0.05)。两组治疗后血清Scr、BUN、UA、
MMP-9、MMP-3、TIMP-l 水平均显著降低，且试验组显著低于对照组(P＜0.05)，Ccr 水平升高，且试验组显著高于对照组(P＜
0.05)。对照组不良反应发生率为10.20%，试验组为6.25%，差异无统计学意义(P＞0.05)。结论：百令胶囊联合厄贝沙坦片对膜性肾
病患者的临床疗效显著，安全性较高，可能与其显著降低MMP-9、MMP-3 和TIMP-1 水平有关。 |
| 英文摘要: |
| Objective:To investigate the effect of MMP-9, MMP-3 and TIMP-1 by corbrin capsules combined with irbesartan
tablets in patients with membranous nephropathy.Methods:98 patients with membranous nephropathy in nephrology department from
our hospital were collected and randomly divided into the experiment group and the control group with 49 cases in each group. Patients
in the control group were treated by irbesartan tablets, patients in the experiment group were treated on the base of the control group with
corbrin capsules. The clinical efficacy, serum Scr, BUN, UA, Ccr, urine protein, MMP-9, MMP-3 and TIMP-l levels and adverse
reactions of the two groups were observed and compared before and after treatment.Results:After treatment, the clinical total effective
rate of the control group (81.63%) was significantly lower than the experiment group (95.92%) (P< 0.05). The serum Scr, BUN, UA,
MMP-9, MMP-3 and TIMP-l levels significantly decreased in two groups after treatment, and the indexes in the experiment group were
significantly lower (P<0.05), the Ccr level increased in two groups, and the Ccr level in the experiment group was significantly higher
(P<0.05). The adverse reactions rate of the control group was 14.58%, the experiment group was 6.25%, there was no statistically
significant difference (P>0.05).Conclusion:Corbrin capsules combine with irbesartan tablets in the treatment of patients with
membranous nephropathy is effective with high safety, it can significantly reduce the matrix metalloproteinase-9, 3 and tissue inhibitor of
metalloproteinase1 levels. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
